## PROVIDER BULLETIN



## **AETNA BETTER HEALTH® OF FLORIDA**

261 N. University Drive Plantation, FL 33324

www.AetnaBetterHealth.com/Florida

Date:	April 14, 2023
Purpose:	Provider Bulletin: Inform providers
	about Makena brand update
Subject:	Makena Update
Products:	MMA, LTC, FHK
From:	Provider Relations

## Aetna Better Health® of Florida Makena

Dear Provider,

Aetna Better Health of Florida (ABHFL) would like to inform you that the U.S. Department of Health and Food and Drug Administration (FDA) withdrew approval of brand **Makena** and the generics **effective April 6, 2023**.

This makes it illegal to prescribe/dispense the brand, generic, or compounded product (17P) moving forward. Please be advised that ABHFL will not approve or pay any Makena brand or genetics effective immediately, including through transition of care.

Makena was originally approved to reduce the risk of preterm birth in women who had previously experienced preterm birth. However, it has not shown any clinical benefit in post market studies.

We appreciate the excellent care you provide to our members. Thank you for your continued participation in the Aetna Better Health of Florida network. Please contact our Provider Services line should you have any questions at:

Phone: MMA: 1-800-441-5501

LTC: 1-844-645-7371 FHK: 1-844-528-5815

Email: FLMedicaidProviderRelations@aetna.com

Thank you,

**Aetna Better Health of Florida** 

www.aetnabetterhealth.com/florida

**CONFIDENTIALITY NOTICE:** This message is intended only for the user of the individual or entity to which it is addressed and may contain confidential and proprietary information. If you are not the intended recipient of the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is prohibited. If you received this communication in error, please notify the sender at the phone number above. **NOTICE TO RECIPIENT(S) OF INFORMATION:** Information disclosed to you pertaining to alcohol or drug abuse treatment is protected by federal confidentiality rules (42 CFR Part 2), which prohibit any further disclosure of this information by you without express written consent of the person to whom it pertains of as otherwise permitted by 42 CFR Part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. The federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse patient.